What's new in the management of psoriasis?
Psoriasis treatment is evolving through better understanding of patients with psoriasis and the pathogenesis of the disease itself. Current treatment plans for psoriasis consist of topical medications for mild-moderate or localized psoriasis and more systemic agents for more generalized and moderate-severe psoriasis. New methods of treatment involve not only prescriptions, but patient education and support through organizations such as the National Psoriasis Foundation. The effectiveness of topical treatments have been improved by a better understanding of increasing patients' adherence to medications and new treatments--new vehicles and combination treatments--that enhance patients' adherence behaviors. Phototherapy, with or without an oral retinoid, remains a key component of psoriasis treatment. More convenient and specific monitoring of methotrexate and biologic medications provide these standards of care in psoriasis better and safer patient outcomes. New anti-IL-12/23 therapies offer another more specific option in the management of chronic plaque psoriasis. Dermatologists should recognize and educate patients about the recently recognized association between psoriasis and vascular disease. Psoriasis management can include counseling patients to obtain appropriate screening for cardiovascular risk.
Kinney
M A
MA
Department of Dermatology, Center for Dermatology Research, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
Feldman
S R
SR
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001688:Biological Products / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000209:etiology; D003879:Dermatologic Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004363:Drug Utilization / Q000639:trends; D019317:Evidence-Based Medicine; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007641:Keratolytic Agents / Q000627:therapeutic use; D055118:Medication Adherence; D010353:Patient Education as Topic; D010789:Phototherapy / Q000379:methods*; D010817:Physician-Patient Relations; D011565:Psoriasis / Q000150:complications / Q000209:etiology / Q000473:pathology / Q000628:therapy*; D012176:Retinoids / Q000627:therapeutic use; D012307:Risk Factors
D000893:Anti-Inflammatory Agents; D001688:Biological Products; D003879:Dermatologic Agents; D007166:Immunosuppressive Agents; D007641:Keratolytic Agents; D012176:Retinoids